Related Experiment Video

Updated: May 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Comparative effectiveness of cholesteryl ester transfer protein (CETP) inhibitors on cardiovascular outcomes: A

Ibrahim Khalil1, M Rafiqul Islam2, Sunjida Amin Promi3

  • 1Dhaka Medical College and Hospital, Dhaka, Bangladesh.

Medicine
|May 19, 2026
PubMed

Insights

This network meta-analysis found Evacetrapib and Anacetrapib to be the most effective cholesteryl ester transfer protein (CETP) inhibitors for improving cardiovascular outcomes. Dalcetrapib also showed benefits for specific cardiovascular events.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Biostatistics

Background:

  • Cardiovascular disease (CVD) is a leading global cause of mortality.
  • Residual cardiovascular risk persists despite current pharmacological treatments.
  • Cholesteryl ester transfer protein (CETP) inhibitors show potential for lipid profile improvement, but comparative effectiveness for cardiovascular outcomes is unclear.

Purpose of the Study:

  • To conduct a network meta-analysis and meta-regression evaluating the comparative effectiveness of CETP inhibitors.
  • To assess the impact of Evacetrapib, Anacetrapib, Dalcetrapib, and Torcetrapib on cardiovascular outcomes.
  • To identify the most effective CETP inhibitors for reducing cardiovascular mortality and major adverse cardiovascular events.

Main Methods:

  • Bayesian network meta-analysis of 10 randomized controlled trials.
  • Inclusion of 84,134 patients with cardiovascular disease or high cardiovascular risk.
  • Network meta-regression to analyze the influence of covariates like age, sex, and baseline lipid levels.

Main Results:

  • Evacetrapib demonstrated the highest ranking for reducing cardiovascular mortality (SUCRA: 71.91%).
  • Anacetrapib showed the best performance in reducing major adverse cardiovascular events (SUCRA: 84.25%) and myocardial infarction (SUCRA: 86.06%).
  • Dalcetrapib exhibited favorable effects on all-cause mortality (SUCRA: 67.51%) and stroke (SUCRA: 83.03%).

Conclusions:

  • Evacetrapib and Anacetrapib emerge as the most promising CETP inhibitors for enhancing cardiovascular outcomes.
  • Dalcetrapib may offer benefits for specific cardiovascular endpoints.
  • Further research is warranted to validate these findings and guide clinical practice.
Abstract

Keywords:
Bayesian network meta-analysisCETP inhibitorsMACEcardiovascular mortalitylipid profiles

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...